CAR T-Cell Manufacturing Timing for Memory-Preserving Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The manufacture of gene-modified T cells for adoptive cell transfer therapy is a complex process, requiring improved methods to enhance product quality and maximize therapeutic efficacy.
Innovation Solution
A method involving contacting T cells with agents that stimulate CD3/TCR and costimulatory molecules, followed by nucleic acid transduction within a defined time frame, and subsequent harvesting, to enhance CAR expression and maintain specific cell populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If T cells are transduced with CAR-encoding nucleic acid molecules using conventional methods, then CAR-expressing cells are produced, but the manufacturing process is complex and inefficient with low productivity
Solution Approach 1:
The patent applies preliminary action by activating T cells with anti-CD3/TCR and anti-CD28 antibodies before transduction with CAR-encoding nucleic acids. This pre-activation step prepares the T cells in advance to enhance transduction efficiency and CAR expression, thereby improving productivity while streamlining the overall manufacturing process
2Productivity
If T cells are expanded in vitro for extended periods to increase cell numbers, then productivity increases, but the balance of naive and memory cell populations is disrupted and product quality decreases
Solution Approach 1:
The patent implements continuous useful action by maintaining T cell activation and proliferation through sustained presence of anti-CD3/TCR and anti-CD28 antibodies along with IL-2 cytokine during the transduction and early expansion phases. This continuous stimulation enables rapid cell multiplication while preserving the natural naive and memory cell population balance, achieving both high productivity and product quality within a compressed timeframe of 7-14 days
3Reliability
If transduction with viral vectors is performed to enhance CAR expression, then therapeutic efficacy improves, but the risk of viral contamination and manufacturing complexity increases
Solution Approach 1:
The patent uses lentiviral vectors as an intermediary carrier to deliver CAR-encoding nucleic acids into T cells. The lentiviral vector system serves as a safe mediator that enables efficient transduction and sustained CAR expression while incorporating safety features to minimize viral contamination risks, thus achieving both high therapeutic efficacy and safety
Solution Approach 2:
The patent optimizes transduction parameters including multiplicity of infection (MOI), transduction duration, and combination with activation stimuli (anti-CD3/TCR and anti-CD28 antibodies) to maximize CAR expression efficiency. By carefully controlling these parameters, the method achieves high therapeutic efficacy while minimizing the need for high viral doses that could increase contamination risks
4Manufacturing precision
If the manufacturing process is extended to improve CAR expression levels, then product quality increases, but the time required for production increases
Solution Approach 1:
The patent applies preliminary action by pre-activating T cells with anti-CD3/TCR and anti-CD28 antibodies before transduction. This preparation step primes the T cells to rapidly express CAR upon transduction, achieving high CAR expression levels within a compressed 7-14 day manufacturing timeline rather than requiring extended culture periods
Solution Approach 2:
The patent maintains continuous useful action by sustaining T cell activation signals and providing IL-2 cytokine support throughout the transduction and early expansion phases. This continuous stimulation ensures high and sustained CAR expression levels are achieved rapidly, optimizing both product quality and production speed
Data Source
AI summary
The present disclosure pertains to methods of making immune effector cells (for example, T cells or NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods. Also disclosed herein are methods of using such compositions for treating a disease, for example, cancer, in a subject.